Clinical Trial Update: Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating senaparib in combination with temozolomide for ARID1A mutation–associated ovarian cancer and related peritoneal cancers is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Senaparib (senaparib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Ovary Cancer, Fallopian Tube Cancer | Phase 2 | Status: RECRUITING